Abstract ID: 26-421
A Case of Horner Syndrome in a Patient Receiving Adalimumab
Author: Yew Ern Au Base Hospital / Institution: Queen Elizabeth Hospital King’s Lynn
Presentation Type: ePoster Presentation
Purpose
Horner Syndrome is defined and classified by the disruption of sympathetic innervation from the hypothalamus to the eye through the classic miosis, ptosis and apparent enophthalmos. Medications can be a rare cause of Horner Syndrome and this case report describes a rare and atypical cause of Horner Syndrome thought to be associated with Adalimumab.
Methods
A 44-year-old female presented to ophthalmology clinic with an 8-month history of a left left upper lid ptosis, and a 2-month history of left pupillary miosis . There was no history of trauma, change in vision, cough, haemoptysis, head/neck pain, or neck masses/lymphadenopathy.. She had a medical history of psoriasis and was a smoker of 20 cigarettes a day. Examination revealed left frontalis overactivity (elevated brow), a 1-2mm left sided ptosis and 2mm anisocoria, with the left pupil being smaller, a visual acuity of 6/4 in both eyes. Intraocular pressures and retinal examination were normal.
Apraclonidine testing demonstrated reversal of anisocoria, supporting a diagnosis of left Horner syndrome. Subsequent cocaine testing showed failure of dilation of the left pupil, further supporting sympathetic denervation.
MRI Head/Neck & Chest X-Ray were unremarkable. Anti-Nuclear Antibody (ANA) Screen was positive (1:1280 titre). Anti-DsDNA IgG antibodies elevated (21.9 IU/mL).
Results
A joint decision to stop adalimumab and switch to Apremilast was made.
Cessation of adalimumab resulted in a self-reported almost complete resolution of anisocoria. The partial resolution following withdrawal of adalimumab raises the possibility of a reversible immune-mediated autonomic neuropathy, potentially affecting the postganglionic sympathetic pathway. However, pharmacological localization was not performed.
Conclusion
This rare case presents a possible iatrogenic cause of Horner Syndrome, with a link to Adalimumab therapy. The clinical course is most suggestive of a reversible peripheral/postganglionic sympathetic dysfunction.
Additional Authors
| First name | Last name | Base Hospital / Institution |
|---|---|---|
| Ebube | Obi | Royal Gwent Hospital |
| Andrew | Want | Cardiff University |
| Andrew | Feyi-Waboso | Royal Gwent Hospital |
